{"id":"gla5pr-glars-nf1","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL398893","moleculeType":"Small molecule","molecularWeight":"112.08"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug exploits a synthetic lethal interaction where NF1-deficient cells become dependent on glutaminyl-tRNA synthetase for survival. By inhibiting this enzyme, GLA5PR GLARS-NF1 selectively kills NF1-mutant tumor cells while sparing normal cells, providing a targeted approach to NF1-associated malignancies.","oneSentence":"GLA5PR GLARS-NF1 is a glutaminyl-tRNA synthetase (GlnRS) inhibitor designed to selectively target and inhibit neurofibromatosis type 1 (NF1) mutant cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:57.787Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neurofibromatosis type 1 (NF1)-associated malignancies"},{"name":"NF1-associated plexiform neurofibromas"}]},"trialDetails":[{"nctId":"NCT03221907","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2016-04-11","conditions":"Pain of Mononeuropathy","enrollment":352},{"nctId":"NCT02952937","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2016-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT02955472","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2016-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT02326987","phase":"PHASE1","title":"A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2013-10","conditions":"Healthy","enrollment":30},{"nctId":"NCT02327000","phase":"PHASE1","title":"A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2014-10","conditions":"Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo (for GLA5PR GLARS-NF1)"],"phase":"phase_3","status":"active","brandName":"GLA5PR GLARS-NF1","genericName":"GLA5PR GLARS-NF1","companyName":"Daewon Pharmaceutical Co., Ltd.","companyId":"daewon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GLA5PR GLARS-NF1 is a glutaminyl-tRNA synthetase (GlnRS) inhibitor designed to selectively target and inhibit neurofibromatosis type 1 (NF1) mutant cells. Used for Neurofibromatosis type 1 (NF1)-associated malignancies, NF1-associated plexiform neurofibromas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}